68Ga-PSMA-HBED-CC在肿瘤与正常组织中的定量重测信度研究
该研究在转移性前列腺癌受试者中开展重测试验,评估68Ga-PSMA-HBED-CC PET/CT定量参数的重复性。18例受试者(16例显示局部或转移性疾病)共分割136个病灶。骨病灶SUVmax的wCV为11.7%,淋巴结为13.7%;骨病灶RC为±32.5% SUVmax,淋巴结为±37.9% SUVmax。结论认为该示踪剂重复性类似18F-FDG,可能可用于治疗反应监测。
要点
- 骨病灶SUVmax的wCV为11.7%,淋巴结病灶为13.7%。
- 骨病灶RC为±32.5% SUVmax,淋巴结病灶为±37.9% SUVmax,超出此范围的变化更可能反映真实生物学改变。
- 唾液腺和脾脏SUVmean的wCV分别为8.9%和10.7%。
核心结论
- 68Ga-PSMA-HBED-CC PET/CT在骨和淋巴结病灶中SUVmax的wCV为12%-14%,RC为±33%-38% SUVmax,与18F-FDG报道值相似,提示可能可用于治疗反应监测。
研究设计与样本
- 研究为在转移性前列腺腺癌受试者中开展的重测试验,受试者在14天内(平均6±4天)接受2次68Ga-PSMA-HBED-CC PET/CT扫描。
- 由2名阅片者分别分割骨、淋巴结、前列腺/床、内脏器官病灶以及代表性正常组织(唾液腺和脾脏),计算SUVmax和SUVmean的绝对差与百分比差异。
主要发现
- 共评估18例受试者,其中16例在68Ga-PSMA-HBED-CC PET/CT上显示局部或转移性疾病。
- 共分割136个病灶,包括骨(n=99)、淋巴结(n=27)、前列腺/床(n=7)和内脏(n=3)。
- 骨病灶SUVmax的wCV为11.7%,淋巴结病灶为13.7%。
- 骨病灶RC为±32.5% SUVmax,淋巴结病灶为±37.9% SUVmax,即两次测量间95%的正常变异在此范围内。
- 唾液腺和脾脏SUVmean的wCV分别为8.9%和10.7%。
关键数值与推荐
- 骨病灶SUVmax的wCV为11.7%,RC为±32.5% SUVmax。
- 淋巴结病灶SUVmax的wCV为13.7%,RC为±37.9% SUVmax。
- 唾液腺SUVmean的wCV为8.9%,脾脏SUVmean的wCV为10.7%。
临床怎么用
- 解读68Ga-PSMA-HBED-CC PET/CT随访时,骨病灶SUVmax变化超过±32.5%、淋巴结病灶超过±37.9%更可能归因于真实生物学改变而非测量变异。
- 该重复性数据支持将68Ga-PSMA-HBED-CC PET/CT定量参数作为潜在影像生物标志物用于治疗反应监测。
局限性
- 研究样本量较小(18例受试者,136个病灶),且内脏病灶(n=3)和前列腺/床病灶(n=7)数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The PET radiotracer 68Ga-PSMA (prostate-specific membrane antigen)-HBED-CC (N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid) shows potential as an imaging biomarker for recurrent and metastatic prostate cancer. The purpose of this study was to determine the repeatability of 68Ga-PSMA-HBED-CC in a test-retest trial in subjects with metastatic prostate adenocarcinoma. Methods: Subjects with metastatic prostate cancer underwent 2 PET/CT scans with 68Ga-PSMA-HBED-CC within 14 d (mean, 6 ± 4 d). Lesions in bone, nodes, prostate/bed, and visceral organs, as well as representative normal tissues (salivary glands and spleen), were segmented separately by 2 readers. Absolute and percentage differences in SUVmax and SUVmean were calculated for all test-retest regions. Repeatability was assessed using percentage difference, within-subject coefficient of variation (wCV), repeatability coefficient (RC), and Bland-Altman analysis. Results: Eighteen subjects were evaluated, 16 of whom demonstrated local or metastatic disease on 68Ga-PSMA-HBED-CC PET/CT. In total, 136 lesions were segmented in bone (n = 99), nodes (n = 27), prostate/bed (n = 7), and viscera (n = 3). The wCV for SUVmax was 11.7% for bone lesions and 13.7% for nodes. The RC was ±32.5% SUVmax for bone lesions and ±37.9% SUVmax for nodal lesions, meaning 95% of the normal variability between 2 measurements will be within these numbers, so larger differences are likely attributable to true biologic changes in tumor rather than normal physiologic or measurement variability. wCV in the salivary glands and spleen was 8.9% and 10.7% SUVmean, respectively. Conclusion: Repeatability measurements for PET/CT test-retests with 68Ga-PSMA-HBED-CC showed a wCV of 12%-14% SUVmax and an RC of ±33%-38% SUVmax in bone and nodal lesions. These estimates are an important aspect of 68Ga-PSMA-HBED-CC as a quantitative imaging biomarker. These estimates are similar to those reported for 18F-FDG, suggesting that 68Ga-PSMA-HBED-CC PET/CT may be useful in monitoring response to therapy.
引用
- Pollard JH, Raman C, Zakharia Y, et al. Quantitative Test-Retest Measurement of 68Ga-PSMA-HBED-CC in Tumor and Normal Tissue. J Nucl Med. 2019. PMID: 31806776. doi:10.2967/jnumed.119.236083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。